Journal article
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, BJ Dezube, PA Jänne, DB Costa, M Varella-Garcia, WH Kim, TJ Lynch, P Fidias, H Stubbs, JA Engelman, LV Sequist, WW Tan, L Gandhi, M Mino-Kenudson Show all
New England Journal of Medicine | Published : 2010
Abstract
BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase. METHODS: After screening tumor samples from approximately 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, we identified 82 patients with advanced ALK-positive disease who were eligible for the clinical trial. Most of the patients had received previous treatment. These pa..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Supported by Pfizer; by grants from the Massachusetts General Hospital (MGH) Cancer Center, the Aid for Cancer Research Foundation, and from an anonymous donor (to MGH); grants from the National Cancer Institute (CA090578, to MGH, Dana-Farber Cancer Institute [DFCI], and Beth Israel Deaconess Medical Center [BIDMC]) and the National Institutes of Health (R01CA136851, to DFCI); a Career Development Award from the American Society of Clinical Oncology (ASCO) Cancer Foundation (to BIDMC); Clinical Investigator Team Leadership Awards from the NCI-ASCO Cancer Foundation (CA47179, to Memorial Sloan-Kettering Cancer Center; and CA06516, to DFCI); a John and Carol Barry Award (to Dr. Kwak); and grants from the National Cancer Institute (CA58187 and CA46934, to the University of Colorado Cancer Center).